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Abstract
Background: The presence of anti-endothelial cell antibodies and pathogenic T cells may reflect an autoimmune
component in the pathogenesis of emphysema. Whether immune modulatory strategies can protect against the
development of emphysema is not known.
Methods: Sprague Dawley rats were immunized with human umbilical vein endothelial cells (HUVEC) to induce
autoimmune emphysema and treated with intrathymic HUVEC-injection and pristane. Measurements of alveolar
airspace enlargement, cytokine levels, immuno histochemical, western blot analysis, and T cell repertoire of the
lung tissue were performed.
Results: The immunomodulatory strategies protected lungs against cell death as demonstrated by reduced
numbers of TUNEL and active caspase-3 positive cells and reduced levels of active caspase-3, when compared with
lungs from HUVEC-immunized rats. Immunomodulatory strategies also suppressed anti-endothelial antibody
production and preserved CNTF, IL-1alpha and VEGF levels. The immune deviation effects of the intrathymic
HUVEC-injection were associated with an expansion of CD4+CD25+Foxp3+ regulatory T cells. Pristane treatment
decreased the proportion of T cells expressing receptor beta-chain, Vb16.1 in the lung tissue.
Conclusions: Our data demonstrate that interventions classically employed to induce central T cell tolerance
(thymic inoculation of antigen) or to activate innate immune responses (pristane treatment) can prevent the
development of autoimmune emphysema.
Background
It is now increasingly recognized that chronic obstruc-
tive pulmonary disease (COPD)/emphysema presents
clinically as a syndrome with pulmonary and extra-
pulmonary manifestations [1,2]. Chronic inflammatory
mechanisms are being discussed as important factors
which either trigger or maintain this chronic disorder
[3-5]. Both lymphocytic infiltration of the bronchial
mucosa and lung parenchyma [6,7] as well as lymph fol-
licles in close proximity to bronchioles have been
described [8]. It has been hypothesized that there may
be an autoimmune component to the chronic progres-
sive lung tissue destruction which can persist after
smoking cessation [9-12]. Recently Lee and co-workers
demonstrated anti-elastin autoantibodies in patients
with tobacco smoking-induced emphysema [13].
Autoimmune diseases result from the propagation of
self-reactive T and B lymphocytes that recognize self-
antigens and mediate tissue destruction.
Our group has described a rat autoimmune emphy-
sema model which is characterized by anti-endothelial
cell antibodies (AECA) and pathologic T lymphocytes,
since both plasma as well as splenocytes have been
shown to trigger emphysema after passive transfer into
healthy naïve rodents [14], suggesting that the pre-
existing T cell repertoire in the lung is not sufficient to
respond to xenogeneic antigens. We reasoned that this
autoimmune model of emphysema, which is based on
immunization of rats with xenogeneic human umbilical
vein endothelial cells (HUVEC), can be utilized to
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because autoimmunity is due to the breakdown of cen-
tral and/or peripheral tolerance. If so, then demonstra-
tion of protection against emphysematous lung
destruction by immune modulation would provide dis-
tinct support for the role of an autoimmune contribu-
tion to lung destruction in this rodent model [14]. This
concept has been repeatedly demonstrated in the NOD
(non-obese diabetic) model of autoimmune diabetes in
which multiple interventions in young mice skew the
immune response and prevent disease [15,16].
In the present study, we utilize interventions classi-
cally employed in experimental autoimmune models to
induce central T cell tolerance by thymic inoculation of
antigen [17] and to activate innate immune responses
with pristane [18]. The acquisition of T cell tolerance to
self occurs primarily within the thymus [19,20] and can
be achieved through 3 not mutually exclusive mechan-
isms: clonal deletion, clonal anergy and specific suppres-
sion. Intrathymic tolerance induction by inoculation of
donor bone marrow cells, spleen cells and other type of
cells has been successfully used to prolong the survival
of cardiac, skin and islet allografts in adult rodents
[20-23]. Here we expand previous studies by utilizing an
intrathymic inoculation approach in our animal model
of autoimmune emphysema. The hydrocarbon oil adju-
vant pristane has been shown to induce a persistent
decrease in phytohemagglutinin responsiveness, consis-
tent with a block of polyclonal T cell proliferation [18].
By demonstrating that early immunomodulation pre-
vents experimental emphysema in pathogen-free ani-
mals, the concept that autoimmune injury may
contribute to clinical emphysema is further bolstered.
Methods
Experimental protocols
The experimental protocol was approved by the Animal
Care and Use Committee of the University of Colorado
Denver. In our study we used 6 week old male Sprague-
Dawley rats (body weight 200 g). Animals were divided
into four groups (n = 6 per group): (1) control group
(IP injection of phosphate buffered saline (PBS)), (2)
HUVEC (H group) alone (10 × 10
6 cells, single IP injec-
tion[14]), (3) intrathymic injection of HUVEC (H-T-H
group) (200,000 cells) 2 weeks prior to immunization
with HUVEC; (4) pristane (H-P group) (200 μl, single IP
injection) 3 days prior to immunization with HUVEC.
Pristane (2,6,10,14-tetramethyl-pentadecane) was pur-
chased from Sigma-Aldrich Co. (St. Louis, MO). While
in our previous study we performed immunization with
adjuvant Titermax Gold, later we found out that
HUVEC itself are strong immunogens and no adjuvant
is needed for antibody production. In the present study
we omitted this step of adjuvant administration.
Primary cultures of HUVEC were isolated in our
laboratory following procedures described by Bruneel
et al [24].
Intrathymic injections
Intrathymic injections were performed under anesthesia
induced with a combination of ketamine(100 mg/kg)/
xylazine (15 mg/kg). The thymus gland was exposed
through a small incision above the sternum and 200,000
HUVEC cells in 100 μl of PBS were injected into thymic
lobes (50 μl/per lobe). The control group received only
PBS injections. The incision was closed with a 4-0 nylon
suture. The injections were performed into 6 week old
rats (body weight 200 g) 2 weeks prior to immunization
with HUVEC. Indeed, these are very young rats and
prior literature [25-27] supports intrathymic injection at
6 weeks.
Tissue processing
All the animals were sacrificed 3 weeks after the IP
HUVEC treatment or PBS injection [14]. Lung tissue
was obtained by opening the chest wall. Lungs were
ligated. The right lung was inflated with 0.5% low melt-
ing agarose at a constant pressure of 25 cmH2Oa n d
fixed in 10% formalin for 48 hr. Lung sections were
embedded in paraffin using standard techniques. The
upper and lower lobes of the left lung were snap-frozen
for protein extraction.
Lung morphology
The 5 μm thick sections were stained with hematoxylin
and eosin. Ten images per slide were acquired at x200
magnification with an AxioCam Color Camera using an
Axioskop 2 Microscope (Carl Zeiss MicroImaging Inc.,
Thornwood, NY). The degree of emphysema was quan-
tified by measuring alveolar airspaces (in pixels per
square micrometer [14]) and mean linear intercept
(MLI; [28]). The CD4+ cell accumulation areas were
measured in pixels per square micrometers. A macro
was created to automate the segmentation, processing,
and quantification steps. For each animal, 10 fields at a
magnification of x100 were captured in a blinded fash-
ion using Carl Zeiss KS300 Imaging System software.
Cell death assessment and western blot (WB) analysis
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) was performed with TACS 2
TdT DAB kit (Trevigen, Gaithersburg, MD) following
manufacturer’s protocol. The ratio of TUNEL-positive
cells to total cells (apoptotic index) was measured asses-
sing more than 3,000 parenchymal cells of each lung
sample in each group [29].
Active caspase-3 was assessed using a rabbit polyclo-
nal antibody to cleaved caspase-3 (Cell Signaling
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staining was performed using VECTASTAIN ABC kit
(Vector Laboratories Inc., Burlingame, CA).
WB analysis was performed as previously described
[14]. Anti-CD19 antibodies were from Santa Cruz Bio-
technology Inc., Santa Cruz, CA, and anti-CD68 from
Serotec Ltd, Oxford, UK.
Cytokine assay
Cytokine levels in whole lung tissue homogenates were
determined using Quantibody Rat-1 Array (RayBiotech,
Inc, Norcross, GA) that allows measurement of the fol-
lowing cytokines: CINC-2 (CXCL3/GROgamma/DCIP-
1), CINC-3 (CXCL3/GRObeta/MIP-2), Fractalkine
( C X 3 C L 1 ) ,C N T F ,G M - C S F ,I L - 1 a, IL-4, LIX (CXCL5),
b-NGF and VEGF.
Lung and spleen T cell isolation
Cells were isolated as described by Finotto et al., [30].
Negative selection of CD4+ T cells was performed using
Rat CD4+ T Cell Enrichment Column from R&D Sys-
tems, Inc. (Minneapolis, MN). The aliquot of the sorted
cell preparation (100 μl) was cytospinned, stained with
Wright stain and counted. The CD4+ T cells isolated
from the lungs were identified by flow cytometry. We
also did the CD3 staining to confirm that the CD4+
cells were T cells and not, for example, strange
macrophages.
Lung CD4+ T cell measurements
Lung sections were stained with an anti-CD4 antibody
and CD4+ cells were counted in 5 different lung fields.
The CD4+ cell accumulation areas were measured in
pixels per square micrometers. A macro was created to
automate the segmentation, processing, and quantifica-
tion steps using a Carl Zeiss KS300 Imaging System
software. A CD4+ T cell count was also performed on
cells isolated from the lungs. A CD4+ T cell count was
also performed on cells isolated from the lungs by flow
cytometry. Both methods gave comparable results.
Flow cytometry
Isolated CD4+ T cells were washed in PBS supplemen-
ted with 1% bovine serum albumin (BSA) (FACS buffer)
and surface stained with mAbs directed against CD3
(FITC, Invitrogen) and CD4 (APC, Invitrogen or BD)
along with one of the following mAbs to TCR V beta
(8.5, 10, or 16.1 (AbD Serotec) or CD25 (PE, Biolegend)
for 30 min at 4°C as described previously [31]. Cells
were washed in FACS buffer and stained with secondary
antibodies to each TCR V beta (R-PE, Invitrogen). For
intranuclear staining with anti-Foxp3 (PE; eBiosciences),
surface stained cells were washed twice, fixed and per-
meabilized prior to staining with anti-Foxp3. Cells were
washed and resuspended in 1% formaldehyde. The num-
ber of events collected ranged between 1 and 3 million.
Samples were acquired on a FACSCalibur equipped
with 488 nm argon and 633 nm red-diode laser for four
color detection. Analysis was performed using FlowJo
(Treestar) software. Lymphocytes were gated using for-
ward scatter versus side scatter.
Statistical analysis
All data are expressed as mean ± SEM. Statistical analy-
sis was performed with the Statview software package
(SAS Institute Inc., Cary, NC). The comparison between
two groups was performed by employing the Student’s
unpaired t test for independent samples. The values
obtained in the different groups of rats were compared
using one-way ANOVA. Statistical difference was
accepted at p < 0.05.
Results
Immunomodulation strategies protect against airspace
enlargement
As previously reported [14], when compared to lungs
from PBS-injected control animals (Figure 1A), histolo-
gical examination of lung tissue samples demonstrated
diffusely enlarged airspaces in HUVEC-immunized rats
(Figure 1B). In contrast, there was no alveolar space
enlargement in the lungs from animals treated with
either intrathymic HUVEC-injection (Figure 1C) or pris-
tane (Figure 1D) in association with intraperitoneal
HUVEC injection. The quantitative data of alveolar air-
space surface area and mean linear intercept (MLI) from
all treatment groups are shown in Figure 1E and Figure
1F. The sections evaluatedw e r es e l e c t e di nar a n d o m
fashion.
Immunomodulation strategies protect against lung cell
apoptosis
Both of the immunomodulatory treatments protected
lungs against cell death as shown by the reduced
numbers of TUNEL positive cells. Figure 2A shows
PBS-treated control rat lung. When compared to lungs
from HUVEC-immunized rats (Figure 2B), intrathymic
injection of HUVEC followed by HUVEC immunization
(Figure 2C) and pristane treatment (Figure 2D) signifi-
cantly reduced TUNEL-positive cells in the rat lungs.
The quantitative analysis of TUNEL positive cells is
shown as an apoptotic index (Figure 2E).
Immunomodulation strategies reduce lung inflammation
and prevent caspase-3 activation
Earlier we have reported [14] that during the first week
of the immunization there was no difference in the
numbers of CD19 or CD68 cells in immunized or con-
trol rat lungs. However, the accumulation of B cells
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weeks after HUVEC-injection. The number of these
cells in the lung tissue was attenuated by intrathymic
HUVEC-injection (Figure 3B) and pristane treatment
(Figure 3C). The accumulation of macrophages as
shown by immunohistochemistry for CD68 in HUVEC-
immunized rat lungs (Figure 3D) was reduced by
intrathymic HUVEC-injection (Figure 3E) and pristane-
treatment (Figure 3F).
Because TUNEL staining detects both apoptotic and
necrotic cells, to identify apoptotic events in the lung
tissue, we performed immunohistochemistry (IHC) for
active caspase-3 (Figure 3G - HUVEC-immunized; Fig-
ure 3H - intrathymic HUVEC-injection and Figure 3I
pristane-treated rat lungs). The number of active cas-
pase-3 positive cells was markedly reduced by both of
the tolerizing strategies.
We confirmed the IHC findings by performing quanti-
tative Western blot (WB) analysis of whole lung tissue
extracts. The levels of activated caspase-3, CD68 and
CD19 were significantly higher in the HUVEC-immu-
nized rats compared to the PBS-treated controls (Figure
3J). The induction of central tolerance with intrathymic
HUVEC-injection and the immunomodulatory strategy
using pristane attenuated the expression of caspase-3 as
well as the expression of CD68 and CD19.
Immunomodulation and T cells
Usually, in normal rat lung, very few CD4+ T cells can
be found (Figure 4A). Conversely, in HUVEC-injected
rat lungs there is a significant accumulation of CD4+ T
cells (Figure 4B). Tolerizing strategies such as thymic
injection of antigen (Figure 4C) and pristane treatment
(Figure 4D) reduced the CD4+ cell numbers to the nor-
mal level. We have quantified the accumulation of CD4
Figure 1 Morphology of rat lungs and alveolar airspace
measurements. Hematoxylin and eosin (H&E) staining of rat lungs
(n = 6 in each group): (A) PBS-treated control (PBS); (B) HUVEC-
immunized (H); (C) Intrathymically HUVEC-injected and HUVEC-
immunized (H-T-H); (D) Pristane-treated 3 days prior to HUVEC-
immunization (H-P). (E) Quantitation of mean alveolar airspace area
(micrometer
2); (F) Mean linear intercept (MLI). Magnification x200.*p
< 0.05 compared to control and each of tolerized rat groups.
Figure 2 Apoptosis in rat lungs and apoptotic index. Cell death
in rat lungs (n = 6) assessed by TUNEL staining. (A) PBS-treated
control; (B) HUVEC-immunized; (C) Intrathymically HUVEC-injected
and HUVEC-immunized; (D) Pristane-treated 3 days prior to HUVEC-
immunization. (E) The apoptotic index (%) was calculated as the
ratio of TUNEL-positive cells to total lung cells. Magnification x400.
*p < 0.05 compared to control and each of tolerized rat groups.
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ging System software. As shown in Figure 4E, there was
almost a 3-fold increase in the CD4+ T cell numbers in
the HUVEC-immunized rat lungs when compared to
untreated controls or rats treated with thymic injection
of antigen or with pristane lungs. CD4+ cells from 4
rats per group were counted.
Pristane treatment suppresses specific T cell receptor
(TCR) expression
Pristane treatment decreased numbers of CD4+ T cells
in the lung tissue. Here we have tested whether pristane
treatment affected T cell receptor expression in the lung
by testing the expression of TCR Vb16.1, TCR Vb8.5
and TCR Vb10 in the treated and untreated HUVEC-
immunized rat lungs. There was a higher expression of
TCR Vb8.5 in lungs and spleens from pristane-treated
and HUVEC-immunized rats when compared to normal
controls. The expression of TCR Vb10 was similar in all
3 groups. While there was no significant difference in
TCR Vb expression on CD4+ T cells obtained from
lung and spleen of normal controls and HUVEC-immu-
nized animals (n = 4 rats per group), there was a
significantly decreased expression of Vb16.1 in both
Figure 3 Immunostaining for B cells (CD19), macrophages (CD68) and active caspase-3 and western blot (WB) analysis.C D 1 9( A-C);
CD68 (D-F) and active caspase-3 (G-I) of HUVEC-immunized (A, D, G); intrathymically HUVEC-injected and HUVEC-immunized (B, E, F); and
pristane-treated 3 days prior to HUVEC-immunization (C, F, I) rat lung sections. Magnification x400. (J) Quantitative WB analysis of rat lung tissue
homogenates for CD19, CD68 and active caspase-3. *p < 0.01 compared to control or immune tolerized rats.
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treated rats compared to rats receiving only HUVEC
(Table 1). Similar findings were seen with the intrathy-
mic injection of HUVEC prior to IP immunization in
lungs and spleen (9.03 ± 0.94% and 8.83 ± 0.47% respec-
tively) when compared to HUVEC-immunized rats
(11.5 ± 0.88% and 12.1 ± 0.4%; p ≤ 0.03 and p ≤ 0.007).
Since HUVEC-immunized rats have 3-times more of
such CD4+ T cells in the lungs, these findings might
suggest that pristane and intrathymic injection of
HUVEC targeted a specific CD4+ T cell subset and raise
the possibility that CD4+ T cells expressing TCR Vb16.1
may represent the pathogenic T cell population.
Intrathymic injection of antigen prior to immunization
induces expansion of regulatory T (Treg) cells
Recent findings indicate that targeted deletion of Treg
cells causes spontaneous autoimmune disease in mice,
whereas augmentation of Treg-cell function can prevent
the development of - or alleviate - variants of experi-
mental autoimmune encephalomyelitis [32]. As shown
in Table 2 levels of Foxp3+/CD25+/CD4+ Treg cells in
the normal control rat lungs and spleen are extremely
low. However, intrathymic injection of antigen prior to
IP immunization resulted in a significantly increased
percentage of Foxp3-expressing CD4+CD25+ Treg cells
when compared with HUVEC-immunized rats, suggest-
ing that the induction of central tolerance results in an
expansion of naturally-occurring Treg cells (n = 4 rats
per group).
Pristane treatment ameliorated the increase in lung tissue
cytokine levels
To examine whether induction of immune deviation by
pristane can affect lung cytokine levels in lung tissue
homogenates, we used Quantibody Rat-1 Array that
allows measurements of the following cytokines: cyto-
kine induced neutrophil chemoattractant-2 (CINC-2
also known as CXCL3/GROgamma/DCIP-1); cytokine
induced neutrophil chemoattractant-3 (CINC-3 also
known as CXCL3/GRObeta/MIP-2); Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF); lipo-
polysaccharide-induced CXC chemokine (LIX also
known as CXCL5); interleukin-4 (IL-4); interleukin
1alpha (IL-1a); ciliary neurotrophic factor (CNTF); Frac-
talkine (CX3CL1), nerve growth factor beta (b-NGF)
and vascular endothelial growth factor (VEGF).
HUVEC-immunization resulted in a greater than 40-fold
increase in IL-1a, and a decrease in vascular endothelial
growth factor (VEGF) and CNTF, levels (Figure 5A),
whereas pretreatment with pristane preserved the nor-
mal VEGF and CNTF levels in the lung and significantly
decreased IL-1a, levels in the HUVEC-immunized
animals.
Immunomodulation strategies protect abolished AECA
production
Earlier we have demonstrated [14], that serum from
HUVEC-immunized animals contains antibodies that
bind to several HUVEC proteins. Induction of central
tolerance achieved by intrathymic injection of HUVEC
prior to IP immunization or immunomodulatory therapy
with pristane abolished antibody production in the
treated rats (Figure 5B). Pre-immune serum did not
cross-react with HUVEC proteins. Thus, these findings
suggest that the central and peripheral immunomodula-
tory strategies resulted in a reduction in lung inflamma-
tion characterized by a reduced recruitment of
Figure 4 Immunostaining for CD4+ T cells.
Immunohistochemistry for CD4+ T cells in PBS-treated (A); HUVEC-
immunized (B); intrathymically HUVEC-injected and HUVEC-
immunized (C); and pristane-treated 3 days prior to HUVEC-
immunization (D) rat lung sections. Magnification x400. (E) The CD4
+ cell accumulation areas were measured in pixels per square
micrometers. A macro was created to automate the segmentation,
processing, and quantification steps. For each animal (n = 4), 10
fields at a magnification of x100 were captured in a blinded fashion
using Carl Zeiss KS300 Imaging System software. *p ≤ 0.002 when
compared to immune tolerized rats.
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in response to intraperitoneal HUVEC injection.
Discussion
It has been shown by several groups that alveolar septal
cells in the lungs from patients with severe emphysema
are undergoing apoptosis [29,33,34], and that induction
of apoptosis in mouse lungs indeed causes emphysema-
tous changes [35]. Alveolar septal cell apoptosis is likely
the consequence of oxidative stress [36], withdrawal of
the impact of lung cell survival factors [28] and/or the
action of proteases [37]. We have recently shown that
alveolar septal cell apoptosis also occurs in our rat auto-
immune emphysema model [1 4 ] .H e r ew ea p p l ye s t a b -
lished immune modulating strategies [19,38,39] to
demonstrate that immunity-skewing approaches can
modify the autoimmune response to HUVEC immuniza-
tion, reduce lung cell apoptosis and prevent airspace
enlargement.
The thymus plays an important role in acquired toler-
ance [40], and several studies show that intrathymic
injection of alloantigens or autoantigens induces specific
systemic tolerance in experimental autoimmune models
[17,41]. The mechanism by which intrathymic injection
of antigen results in systemic tolerance is still elusive,
although injection of antigen into the thymus induces
apoptosis of thymic T cells [42]. In addition, an increase
in clonotype positive T cells in the thymus prevents the
peripheral expansion of antigen-specific CD4+ T cells
[43] and induces prolonged anergy [44].
The CD4
+ CD25
+ regulatory population of T cells
(Treg cells), which expresses the forkhead family
Table 1 TCR Vb expression on CD4+ T cells (%) from lung and spleen of HUVEC and HUVEC-pristane treated rats
(n = 4)
Vb16.1 Vb10 Vb8.5
Experimental Groups (n = 4) lung spleen lung spleen lung spleen
Control 12.1 ± 0.34 12.7 ± 0.34 9.7 ± 0.29 9.2 ± 0.59 4.2 ± 0.414 4.4 ± 0.59
HUVEC* 11.5 ± 0.88 12.1 ± 0.4 8.22 ± 0.34 8.08 ± 0.61 7.1 ± 1.27 8.4 ± 2.41
HUVEC+Pristane* 7.67 ± 0.47 9.05 ± 0.59 7.1 ± 0.77 5.62 ± 1.68 7.79 ± 1.32 5.7 ± 1.82
*p ≤ 0.008 *p ≤ 0.003 *p ≥ 0.05 *p ≥ 0.05 *p ≥ 0.05 *p ≥ 0.05
Table 2 The percentage of Foxp3-expressing CD25+/CD4
+ T regulatory cells in rat lungs and spleen. CD4+/CD25
+/Foxp3+
Experimental Groups lung spleen
Control 0.69 ± 0.12 0.69 ± 0.03
HUVEC 38.00 ± 1.60 40.60 ± 0.52
Intrathymic-Injection-HUVEC 56.00 ± 0.38 52.7 ± 1.23
p ≤ 0.001 p ≤ 0.001
Figure 5 Effects of Immunomodulatory Strategies on Rat Lung
Cytokine levels and AECA production. (A) Levels of IL-a, VEGF
and CNTF in whole lung tissue homogenates from PBS-treated
controls, HUVEC-immunized and pristane-pretreated/HUVEC-
immunized rats measured by Quantibody Rat-1 Array. *p < 0.01
when compared to the untreated HUVEC-immunized rats. (B)
Antibody production in HUVEC-immunized rats. HUVEC protein
extracts were separated on 4-12% gradient Bis-Tris gel and WB was
performed using serum (at 1:1000 dilution) from HUVEC-immunized
(H) rats (lanes 1 and 2); intrathymically HUVEC-injected and HUVEC-
immunized (H-T-H) rats (lanes 3 and 4); pristane pre-treated/HUVEC-
immunized (H-P) animals (lanes 5 and 6); and pre-immune serum
(lanes 7-10).
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the peripheral tolerance mechanism that protects against
a variety of autoimmune diseases [45]. Here we demon-
strate that intrathymic injection of HUVEC into 6 week
old rats prior to the immunization results in the expan-
sion of CD4+CD25+Foxp3+ Treg cells, suggesting that
an expansion of this regulatory T cell subset may be
one of the mechanisms responsible for the protective
effect against emphysema development. Whether the
mechanism of action for thymic inoculation of HUVEC
is attributable to the intrathymic deletion of endothelial-
reactive T cells or to the increased production of
clonotype-positive T cells is the subject of ongoing
investigations by our group.
In the present experiments, pristane modulated the
immune response triggered by HUVEC immunization
and prevented AECA production as well as lung cell
apoptosis and emphysematous lung destruction. Pristane
is considered as an immunological adjuvant namely in
vaccines and while administration of the high doses of
the hydrocarbon oil adjuvant pristane are used to induce
lupus in a murine model of systemic lupus erythemato-
sus [46] it also has been also shown to induce a persis-
tent decrease in phytohemagglutinin responsiveness,
consistent with a block of polyclonal T cell proliferation
[18]. As an immune adjuvant, we expected pristane to
produce immune skewing. We considered that Toll-like
Receptor (TLR) signaling, which is activated by pristane
(e.g. requirement of TLR 7 for pristane-induced produc-
tion of autoantibodies and development of murine lupus
nephritis [47]) would be upregulated and therefore
immune injury could have been ramped up in the lungs.
We did not know at the outset whether pristane would
exacerbate autoimmunity or ameliorate it and were sur-
prised about the experimental results.
Similar to human emphysema [48], T cells recruited to
t h el u n gi nr e s p o n s et oH U V E Cm i g h te x p r e s sa
restricted TCR repertoire, suggesting their recruitment
to lung in response to a conventional antigenic stimulus.
We queried whether alterations of the TCR repertoire of
lung and spleen CD4+ T cells had occurred as a result
of pristane treatment. Our earlier studies did not find
significantly expanded TCR-Vbeta subsets in ex vivo
human COPD lung samples [48]. However, when cul-
t u r e di nv i t r o ,w ef o u n ds e v e nm a j o rC D 4 - e x p r e s s i n g
TCR-Vbeta subset expansions from five of the patients
with emphysema. This suggested that severe emphysema
is associated with inflammation involving T lymphocytes
that are composed of oligoclonal CD4+ T cells. Here we
show that pristane treatment decreased the percentage
of CD4+ T cells expressing TCR Vb16.1 in the lung
compared to the expression of Vb16.1 on CD4+ T cells
from the lungs of HUVEC-immunized rats. It has been
reported that treatment with antibody directed against
this receptor can facilitate prolonged graft survival [49],
suggesting pathogenic nature of rat TCR Vb16.1. We
would like also to point out that while human and
mouse TCR nomenclature is well characterized in the
Immunogenetics Information System http://www.imgt.
org, rat TCR are not in the system making it difficult to
compare rat TCR repertoire with known nomenclatures
and species.
As with VEGF receptor blockade-induced emphysema
[28], HUVEC immunization also leads to a decrease in
VEGF protein levels in the lung (Figure 5B). VEGF is
likely a critical component of the lung structure mainte-
nance program [50]. Here we demonstrate that pretreat-
ment with pristane abolished antibody production and
preserved normal levels of VEGF in HUVEC-immunized
animals. Moreover, our data indicate that HUVEC
immunization induced the expansion of CD4+ T cells
expressing TCR Vb16.1, which usually are associated
with an allergic response [51]. This expansion was sig-
nificantly blunted upon pre-treatment with pristane,
suggesting that this T cell subset may be the pathogenic
CD4+ T cell subset in this immune model of emphy-
sema. We also found that the expression of ciliary
neurotrophic factor (CNTF) was reduced in HUVEC-
immunized rat lungs (Figure 5A). CNTF is a cytokine of
the interleukin-6 (IL-6) family and its mRNA is widely
expressed in the brain, heart, lung, and liver, of the rat,
in addition to preferential expression in the sciatic nerve
[52]. To our knowledge, this is the first report that
CNTF protein expression is reduced in lungs of HUVEC
immunized rats, and that immunomodulation with pris-
tane prevents this decrease.
Interleukin-1a (IL-1a) is a 19 kDa proinflammatory
cytokine that is a potent mediator of the body’s response
to inflammation, microbial invasion, tissue injury, and
immunological response [53], and has a role in arthritis,
Alzheimer’s disease and tumor growth [54,55]. In this
study, we demonstrated a significant upregulation of IL-
1a levels in the HUVEC-immunized rat lung that was
prevented by pristane treatment (Figure 5A).
Earlier [14] we have demonstrated that HUVEC injec-
tion resulted in the production of antibodies against
endothelial cells. Here we show that in the lungs of
HUVEC-injected rats, the number of B cells and the
expression of cell surface CD19 is increased and that
the immunomodulatory strategies attenuated this
increase (Figure 3). Recently Sato and colleagues [56]
reported that small changes in CD19 expression can
induce autoantibody production and suggested that
modest changes in the expression or function of regula-
tory molecules, such as CD19, may shift the balance
between tolerance and immunity to autoimmunity [56].
It is possible that downregulation of CD19 in B cells,
using immunomodulatory strategies applied by us, also
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mune emphysema. However, it is also possible that the
decrease in CD19 expression could simply reflect
decreased numbers of B cells in the lungs each expres-
sing normal levels of CD19. Taken together, the results
of our experiments show that rats can be made tolerant
to the effects of HUVEC-immunization.
A limitation of our studies is that we have not deli-
neated which specific cell-cell interactions, cytokines,
antioxidants or proteases are involved in developing tol-
erance and whether the different immunomodulatory
strategies converge toward a final signaling pathway.
However, we can conclude that - as there are multiple
factors and conditions which can trigger lung emphy-
sema development [12,57] - there are multiple interven-
tions which can prevent experimental emphysema
development.
Emphysema, until recently, has been seen as a pro-
blem of proteolysis, not of adaptive immunity. Whereas
this is somewhat perplexing because the burning cigar-
ette can be seen as an antigen delivery device, most
recently a concept of emphysema pathogenesis based on
immune mechanisms is emerging [11,12]. Lung gene
expression profiling of cigarette smoke-exposed rats
demonstrated a sustained increased expression of a
number of genes implicated in the innate and adaptive
immune responses [58]. Chronic lung cell damage, and
in particular apoptosis when combined with ineffective
phagocytosis (removal of apoptosed cell bodies) [59],
may result in the generation of neoantigen peptides [60]
and of autoantibodies. Moreover, tobacco anti-idiotypic
antibodies have been identified in serum from smokers
[61], and the recent finding of anti-elastin autoantibo-
dies [13] in patients with tobacco smoking-induced
emphysema, that correlated with severity of the disease,
link emphysema to adaptive immunity against a specific
lung antigen and suggest the potential for autoimmune
pathology.
Whether “priming” strategies can also protect against
other - non-HUVEC-induced forms of emphysema
remains to be investigated. We are intrigued that experi-
mental manipulations as diverse as intrathymic antigen
injection and intraperitoneal delivery of pristane pre-
vented the accumulation of lung B cells and macro-
phages, facilitated the expansion of CD4+CD25+Foxp3+
Treg cells and suppressed the expansion of TCR Vb16.1
expressing T cells in the HUVEC-immunized animals.
W h e t h e ro rn o tT C RV b16.1 expressing T cells are
associated with autoimmune emphysema still need to be
verified. Whether or not this is true in human disease
needs to be determined. Also, the role of macrophages
in this autoimmune emphysema model deserves further
investigation.
Conclusions
The experimental autoimmune emphysema may evolve
from a confluence of subtle multigenic variations in cell
surface signaling molecules. As in NOD diabetes, where
interventions prior to the development of diabetes skew
immune responses and are associated with decreased
inflammation around pancreatic islets and prevent dia-
betes [62,63], here we demonstrate that similar immu-
nomodulatory strategies that suppress autoreactive T
and B cells and upregulate Treg cells can prevent
experimental autoimmune emphysema.
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